Core Insights - PROCEPT BioRobotics is shifting its sales strategy by eliminating end-of-quarter volume discounts to stabilize revenue and improve average selling prices (ASPs) [1][6][8] - The company has treated over 125,000 patients globally and has more than 900 instruments installed, marking a significant milestone with the transition to Category I reimbursement [2][4] - The market for benign prostatic hyperplasia (BPH) presents a large opportunity, with current Aquablation penetration at about 10% of the 400,000 annual prostate procedures [3][4] Financial Targets - For 2026, PROCEPT expects revenue between $390 million and $410 million, representing a growth of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65% [7][26] - The adjusted EBITDA loss is projected to be between $30 million and $17 million, with expectations of positive EBITDA in Q4 2026 [7][26] - The company anticipates over 25% revenue growth in 2027, aiming for a business exceeding $500 million and positive adjusted EBITDA of $25 million to $30 million [7][26] Product and Market Strategy - PROCEPT is pursuing a whole-gland prostate cancer strategy with the pivotal WATER IV trial, which is expected to complete procedures by mid-year and present results at AUA in 2027 [5][19] - The company is focusing on improving handpiece ASP to approximately $3,500 by 2026, which is a $300 increase from historical levels, and aims for a one-to-one alignment of handpiece sales to procedures [9][8] - A commercial reorganization has been implemented to enhance execution by integrating clinical and sales support under a single leadership structure [10][12] Marketing and Patient Engagement - The marketing strategy emphasizes increasing patient awareness and share capture, with current unaided awareness of Aquablation at only 1% to 2% [14][15] - Targeted digital engagement strategies are being developed for medically managed patients, focusing on those who are on BPH medications and have high discontinuation rates [15][16] Operational Improvements - The company has made operational changes to reduce time from purchase order to the completion of initial cases, achieving a 50% reduction in ramp-up time at new sites [12] - PROCEPT plans to offer trade-in credits for older systems to encourage replacements and is exploring leasing pilot programs, although leasing is not expected to be a major part of 2026 [13]

Core Viewpoint - PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is identified as an overlooked small-cap stock with positive sentiment from Wall Street ahead of its fiscal Q4 2025 earnings report, expected on February 24, 2026, with projected quarterly revenue of approximately $372.87 million and a GAAP EPS of $1.56 [1]. Group 1: Analyst Ratings - Ryan Zimmerman from BTIG maintained a Hold rating on PROCEPT without disclosing price targets [2]. - Richard Newitter from Truist Financial reiterated a Buy rating but reduced the price target from $50 to $47 [2]. - 79% of the 14 analysts covering the stock maintain a Buy rating on PROCEPT [5]. Group 2: Market Outlook - Analysts at Truist express optimism for the MedTech sector in 2026 due to attractive valuations compared to other healthcare areas, although concerns exist that the sector may become a source rather than a destination for new healthcare investments [4]. - The 12-month average price target from Wall Street indicates more than 77% upside potential from current levels [5]. Group 3: Company Overview - PROCEPT BioRobotics is a commercial-stage company specializing in surgical robotics solutions for urology, with its flagship product being the AquaBeam Robotic System, designed for minimally-invasive urologic surgeries [5].

Company Overview - PROCEPT BioRobotics is a healthcare technology company specializing in robotic surgical systems for minimally invasive urology procedures, particularly targeting benign prostatic hyperplasia (BPH) treatment [6][9] - The company utilizes proprietary image-guided robotic systems to enhance patient outcomes and hospital efficiency, with a competitive edge stemming from its innovative Aquablation therapy and a growing installed base [6][9] Financial Performance - As of January 26, PROCEPT BioRobotics had a market capitalization of $1.65 billion, with a trailing twelve months (TTM) revenue of $299.91 million and a net income loss of $84.58 million [4] - The company reported a 43% year-over-year revenue increase in the third quarter, amounting to $83.3 million, and a gross margin expansion to 65% [11] - Management provided revenue guidance for 2026, projecting between $410 million and $430 million, indicating potential growth of up to 32% from 2025 levels [11] Recent Transactions - Chicago Capital disclosed a reduction in its stake in PROCEPT BioRobotics by 377,850 shares in the fourth quarter, translating to an estimated transaction value of $12.53 million [2][3] - Following this transaction, Chicago Capital's remaining stake in PROCEPT was valued at $37.47 million, with the position now accounting for 0.93% of its 13F assets, down from 1.38% in the previous quarter [2][3] Stock Performance - As of January 26, PROCEPT BioRobotics shares were priced at $29.61, reflecting a significant decline of 60.4% over the past year, contrasting sharply with the S&P 500's approximate 14% gain during the same period [3][11] - The stock's performance has raised concerns regarding operating losses, high spending, and the pace at which growth can lead to sustainable profitability, as evidenced by an adjusted EBITDA loss of $7.4 million in the quarter [11]

Core Insights - Chicago Capital, LLC increased its stake in Procept BioRobotics by 999,873 shares, totaling 1,568,845 shares valued at $55.99 million as of quarter-end [1][2] - Procept BioRobotics' stock price was $34.61 as of October 21, 2025, reflecting a 48.57% decline year-over-year and underperforming the S&P 500 by 63.63 percentage points [2] - The company reported a revenue increase of 48% year-over-year in Q2, raising its full-year revenue outlook for 2025 to $325.5 million, a 45% increase over 2024 [9][10] Company Overview - Procept BioRobotics specializes in surgical robotics for urology, focusing on treating benign prostatic hyperplasia (BPH) with its AquaBeam Robotic System [4][5] - The company has a market capitalization of $1.95 billion and a trailing twelve months (TTM) revenue of $274.95 million, with a net income of -$84.15 million [3] Investment Rationale - Chicago Capital's significant increase in investment suggests confidence in Procept BioRobotics' growth potential despite recent stock price declines [7][11] - The company's rapid sales growth and attractive price-to-sales ratio of seven may indicate a compelling investment opportunity [10][11]

Core Viewpoint - PROCEPT BioRobotics has appointed Larry L. Wood as the new CEO, succeeding Reza Zadno, who has led the company to significant growth and expansion since 2020 [2][3]. Group 1: CEO Transition - Larry L. Wood, a seasoned executive with 18 years of experience at Edwards Lifesciences, will officially take over as CEO on September 2, 2025 [2][3]. - Under Zadno's leadership, PROCEPT achieved a substantial increase in annual surgical procedures from hundreds to nearly 100,000 for Aquablation therapy [4]. - The company completed an IPO in 2021, raising over $600 million [4]. Group 2: New CEO's Background - Wood has a strong background in the medical device industry, having served as Group President and Corporate Vice President at Edwards Lifesciences, where he was responsible for TAVR and structural heart disease operations [4][5]. - He has a proven track record of leading the development and commercialization of the SAPIEN transcatheter aortic valve replacement system, establishing TAVR as a global standard for aortic stenosis treatment [4][5]. - Wood's personal net worth is estimated at $16.21 million, primarily from his holdings in Edwards Lifesciences [5]. Group 3: Company Focus and Market Potential - PROCEPT BioRobotics specializes in robotic solutions for urology, with its core product, Aquablation Therapy, being the first ultrasound-guided, robot-assisted, non-thermal water ablation therapy for treating BPH [9][10]. - The company aims to expand the global market for Aquablation, with a 48% year-over-year revenue growth reported in Q2 2025 [11]. - PROCEPT has initiated clinical trials for prostate cancer treatment, indicating plans to broaden its product line to address more urological conditions [13]. Group 4: Strategic Advantages - Wood's experience in global commercialization and market entry strategies is expected to accelerate Aquablation's entry into new markets [13]. - His ability to navigate regulatory environments and secure reimbursement for new technologies may facilitate quicker adoption of BPH treatments in various countries [13]. - The company is developing a multi-procedure robotic platform, expanding its capabilities beyond BPH to include other urological diseases [13].